» Articles » PMID: 10794694

Design of a Gag Pentapeptide Analogue That Binds Human Cyclophilin A More Efficiently Than the Entire Capsid Protein: New Insights for the Development of Novel Anti-HIV-1 Drugs

Overview
Journal J Med Chem
Specialty Chemistry
Date 2000 May 5
PMID 10794694
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclophilin A (hCyp-18), a ubiquitous cytoplasmic peptidyl-prolyl cis/trans isomerase (PPIase), orchestrates HIV-1 core packaging. hCyp-18, incorporated into the virion, enables core uncoating and RNA release and consequently plays a critical role in the viral replication process. hCyp-18 specifically interacts with a single exposed loop of the Gag polyprotein capsid domain via a network of nine hydrogen bonds which mainly implicates a 7-mer fragment of the loop. As previously reported, the corresponding linear heptapeptide Ac-Val-His-Ala-Gly-Pro-Ile-Ala-NH(2) (2) binds to hCyp-18 with a low affinity (IC(50) = 850 +/- 220 microM) but a potentially useful selectivity for hCyp-18 relative to hFKBP-12, another abundant PPIase. On the basis of X-ray structures of Gag fragments:hCyp-18 complexes, we generated a series of modified peptides in order to probe the determinants of the interaction and hence to select a peptidic ligand displaying a higher affinity than the capsid domain of Gag. We synthesized a series of heptapeptides to test the energetic contribution of amino acids besides the Gly-Pro moiety. In particular the importance of the histidine residue for the interaction was underscored. We also investigated the influence of N- and C-terminal modifications. Hexapeptides containing either deaminovaline (Dav) in place of the N-terminal valine or substitution of the C-terminal alanine amide with a benzylamide group displayed increased affinities. Combination of both modifications gave the most potent competitor Dav-His-Ala-Gly-Pro-Ile-NHBn (28) which has a higher affinity for hCyp-18 (K(d) = 3 +/- 0.5 microM) than the entire capsid protein (K(d) = 16 +/- 4 microM) and a very low affinity for hFKBP-12. Some of our results strongly suggest that the title compound is not a substrate of hCyp-18 and interacts preferentially in the trans conformation.

Citing Articles

Inhibitors of Cyclophilin A: Current and Anticipated Pharmaceutical Agents for Inflammatory Diseases and Cancers.

Zhao X, Zhao X, Di W, Wang C Molecules. 2024; 29(6).

PMID: 38542872 PMC: 10974348. DOI: 10.3390/molecules29061235.


Refinement and 3D-QSAR Studies of Inhibitors of Cyclophilin A Containing Amide Linker.

Fan F, Zhu J, Ni S, Cheng J, Tang Y, Kang C QSAR Comb Sci. 2020; 28(2):183-193.

PMID: 32327951 PMC: 7168557. DOI: 10.1002/qsar.200860076.


Discovery of novel low-molecular-weight HIV-1 inhibitors interacting with cyclophilin A using in silico screening and biological evaluations.

Tian Y, Verathamjamras C, Kawashita N, Okamoto K, Yasunaga T, Ikuta K J Mol Model. 2012; 19(1):465-75.

PMID: 22949064 PMC: 7088282. DOI: 10.1007/s00894-012-1560-7.


A convenient approach to synthesizing peptide C-terminal N-alkyl amides.

Fang W, Yakovleva T, Aldrich J Biopolymers. 2012; 96(6):715-22.

PMID: 22252422 PMC: 3924563. DOI: 10.1002/bip.21600.